Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 11/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.37 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18927171 | 1.00 | P2RY12 (0.39) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL19762770 | 0.94 | P2RY12 (0.41) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL19250015 | 0.94 | P2RY12 (0.41) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL22219978 | 0.93 | P2RY12 (0.35) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL22879142 | 0.93 | P2RY12 (0.36) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL18927160 | 0.92 | P2RY12 (0.39) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL18917302 | 0.92 | KDM4E (0.37) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL18917307 | 0.92 | KDM4E (0.37) | P2RY12PRMT6ADORA1DNPH1P2RY2 | |
| SCHEMBL31430106 | 0.92 | P2RY12 (0.43) | P2RY12PRMT6ADORA1DNPH1 | |
| SCHEMBL18797869 | 0.92 | TYMP (0.39) | P2RY12PRMT6DNPH1P2RY2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3322713-B1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-10730907-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-04 | — | — | US | disclosed |
| US-10364266-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20180258132-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| EP-3366691-A1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-08-29 | — | — | EP | disclosed |
| US-9994607-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| US-9994607-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | disclosed |
| EP-3322713-A1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-05-23 | — | — | EP | disclosed |
| US-20170233430-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2017-08-17 | — | — | US | disclosed |
| US-20170233430-A1 | Novel Compounds | GLAXOSMITHKLINE LLC | 2017-08-17 | — | — | US | disclosed |
| US-9718848-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-9718848-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-01 | — | — | US | disclosed |
| US-20170158724-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158724-A1 | Novel Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| WO-2017093933-A1 | CYCLIC PURINE DINUCLEOTIDES AS MODULATORS OF STING | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| US-9260424-B2 | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233430-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | P2RY12 86/4885PRMT6 2225/4885ADORA1 209/4885 |
| US-20180258132-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | P2RY12 86/4885PRMT6 2225/4885ADORA1 209/4885 |
| US-10364266-B2 | Compounds | STING1, IRF3, TLR9 | P2RY12 74/4885PRMT6 2517/4885ADORA1 158/4885 |
| US-10730907-B2 | Compounds | STING1, IRF3, TLR9 | P2RY12 74/4885PRMT6 2517/4885ADORA1 158/4885 |
| US-20170158724-A1 | Novel Compounds | STING1, IRF3, IFNAR1 | P2RY12 86/4885PRMT6 2225/4885ADORA1 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.